By This Hour Health Desk
A registered clinical study is set to examine whether Motion Style Acupuncture Treatment, or MSAT, adds benefit for people hospitalized with acute shoulder pain attributed to traffic accidents. The planned trial, listed on ClinicalTrials.gov, would compare an integrative Korean medicine regimen that includes MSAT with the same regimen without the motion-based acupuncture component.
The distinction matters because the study is not testing MSAT in isolation against no care. Both groups are described as receiving integrative Korean medicine, while only one would receive MSAT in addition. If the study is carried out and reported, its comparison could help address a narrower question: whether adding the procedure to the specified treatment package is associated with different patient outcomes over the trial’s planned observation period.
The registry record describes an interventional study involving about 98 hospitalized patients. It lists pain, shoulder movement, daily function, quality of life, satisfaction and safety events among the outcomes to be assessed. But a registered protocol is a plan, not evidence that the planned treatment has proved effective or safe. No trial results are provided in the supplied material, and the record alone cannot establish how participants fared.
The comparison centers on an added procedure, not a stand-alone treatment
MSAT is described in the registry entry as a procedure in which needles are inserted in the shoulder area while the shoulder joint is gently moved. The trial’s focus on this combined action is important when interpreting its purpose. The planned assessment concerns the added role of MSAT within a broader regimen, rather than acupuncture generally, shoulder movement generally, or every form of care for shoulder pain after a traffic accident.
Under the registered design, participants would be randomly assigned to one of two groups. One group would receive integrative Korean medicine plus MSAT. The comparison group would receive integrative Korean medicine without MSAT. Random allocation is a feature of the planned experimental design intended to create a direct group comparison, but the registry information supplied here does not provide results from that comparison.
The common regimen is described as including acupuncture, herbal medicine, pharmacopuncture and Chuna therapy. That shared care package gives the trial a particular interpretive boundary. Any future difference between the groups, if one were reported, would concern MSAT added to that regimen. It would not by itself show that MSAT would have the same effect when delivered outside that setting, paired with a different collection of treatments, or used among patients whose shoulder pain has a different cause.
It also means the eventual findings, if available, would need to be read with attention to the full treatment context. The registry description does not support treating the planned study as a test of a single needle-based intervention divorced from the other care participants are scheduled to receive. Nor does it support claims about which element of the broader regimen is responsible for any change a future report might describe.
A short inpatient course is paired with follow-up after discharge
The listed population consists of approximately 98 people who are hospitalized with acute shoulder pain following a traffic accident. The supplied record does not provide further participant characteristics, and it does not provide outcome data. That leaves substantial limits on what can be concluded now about the people who may enroll or about how well results could apply beyond the defined study group.
Treatment is planned during hospitalization for up to five days. The protocol also describes telephone follow-up at two weeks and one month after enrollment. This creates a schedule that covers the inpatient treatment period and then checks in after enrollment, rather than limiting assessment to the days when participants are receiving the planned intervention in hospital.
The time frame matters because the listed outcomes reach beyond a single pain measure. The investigators plan to assess pain and shoulder movement, but also daily function, quality of life and satisfaction. Safety events are included as well. Together, those categories suggest that any later study report would need to distinguish among several kinds of outcomes rather than reduce the question to one measure alone.
For now, the registry listing does not say whether MSAT produced changes in pain, movement, function, quality of life or satisfaction. It does not report the number or nature of safety events. It also does not show whether planned telephone follow-up was completed. Those absences are consequential: an outcome named in a protocol is not an outcome demonstrated by the study.
Safety is an outcome to be measured, not a conclusion already reached
The inclusion of safety events among the listed outcomes indicates that safety is part of the planned evaluation. It does not establish a safety profile for MSAT, for the larger integrative Korean medicine regimen, or for their use together. The supplied materials do not describe observed adverse events, their frequency, their timing or how any events would compare between the two groups.
That limitation applies equally to efficacy. The registration describes a human interventional study with random assignment, not a completed peer-reviewed research paper. No peer-review status is supplied, and no published results, analysis or conclusion is included in the material available for this report. The appropriate evidence label is therefore a registered planned experimental study in hospitalized human participants, with an intended sample of about 98 people.
Registration can make a study’s stated aims, participant group, planned comparison and selected outcomes visible before results are known. It cannot answer whether recruitment occurred as intended, whether participants received treatment as scheduled, whether the final number enrolled matched the target, or whether the results—if later released—would support the study’s expectations. Those questions require completed-study information, not merely the outline of a protocol.
The record also should not be read as a regulatory authorization or clinical recommendation. The supplied claims identify a ClinicalTrials.gov listing, but provide no statement that any regulator has approved MSAT for this indication or that the registry has made a finding on efficacy or safety. A trial listing records a study; it does not confer proof of benefit, establish acceptable risk, or replace the findings of a completed assessment.
What the planned design may clarify—and what it cannot answer yet
If conducted and reported, the study could provide a more structured comparison of outcomes among the two planned care groups during hospitalization and through the one-month follow-up. The random assignment and the common background regimen are designed around the central question of whether adding MSAT corresponds with different outcomes in this narrowly defined setting. Yet the available description does not disclose any observed effect, whether favorable, unfavorable or absent.
The study’s size and setting also define its scope. Approximately 98 hospitalized patients constitute the intended population, not a broad account of everyone with shoulder pain or everyone injured in traffic accidents. The registration describes acute shoulder pain attributed to traffic accidents; it does not provide evidence about other causes of shoulder pain, other stages of symptoms, or treatment outside the stated hospital-based plan.
Several practical uncertainties remain. The supplied material does not include enrollment progress, completion status, participant-level findings, comparisons between groups, a statistical analysis, or a peer-reviewed manuscript. It does not specify whether every planned outcome will ultimately be reported, whether the scheduled contacts will be completed for all participants, or how any findings might be interpreted alongside the multiple components of care common to both groups.
Readers should therefore separate the study question from a clinical conclusion. The question is whether MSAT, added to the described integrative Korean medicine regimen, affects a set of pain, movement, functional, quality-of-life, satisfaction and safety measures in the planned patient population. The conclusion has not yet been supplied by the registry material. Nothing in the available record establishes that the intervention works, that it does not work, or that it has a defined safety outcome in this setting.
The report is based on the ClinicalTrials.gov record and has not been independently corroborated. It describes a planned study rather than independently verified enrollment, treatment delivery, safety findings or efficacy results. Any future assessment of the intervention would require completed results and careful attention to the study population, the combined treatment regimen, the outcomes reported and the limitations of the final evidence.
For further context on this subject, see Registry lists trial of sirolimus in asymptomatic women who carry ApoE4.
Reporting notes
What is confirmed: The target population is about 98 hospitalized patients, with treatment for up to five days and follow-up through one month.
Why this matters: The listing describes a direct comparison but provides no results, so it cannot establish effectiveness or safety.
What remains unclear: Enrollment, completed outcomes, adverse events, peer-review status and any treatment effect are not supplied. This report is based on one source and has not been independently corroborated.
